SUBSCRIBE
SUBSCRIBE

Metabolomics Market Size 2022 to 2030- Quantitative Research By QYResearch Medical

November 11, 2022 | 
9 min read

The global metabolomics market size was USD 1.88 Billion in 2020 and is expected to register a revenue CAGR of 13.2% during the forecast period.

The global metabolomics market size was USD 1.88 Billion in 2020 and is expected to register a revenue CAGR of 13.2% during the forecast period.

Metabolomics market revenue growth can be attributed to increasing use of metabolomics in the healthcare sector for various research procedures. Rising number of research & development projects, growing global geriatric population, rising number of diabetic patients, and surging awareness about advanced technology are also driving market revenue growth.

Metabolomics is the scientific assessment of chemical procedures including metabolites. It is the exact investigation of uncommon synthetic fingerprints that particular cell processes leave. Metabolomics is an arising field and is broadly characterized as the general estimation of metabolites and low-atomic weight particles in a biological sample. Metabolomics permits bigger quantities of metabolites that are quickly shrouded in customary clinical research center strategies. It can consequently complete inclusion of natural cycles & metabolic pathways. Hence, it keeps on promising to fill in as a crucial target focal point in the atomic magnifying lens for exactness medication.

Metabolites are personally connected to the aggregate of a living being and can be utilized for an expansive scope of utilizations. For instance, considerable proportionality testing, phenotyping of hereditarily changed plants, distinguishing gene functioning, and biotic-abiotic stress response study are some application areas of metabolomics. Additionally, it assists scientists and researchers to compute physiological impacts & notice the unfavorable impact of medications in an organism.

Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118241

Market Dynamics:
Driver: Increasing Funds for Research & Development in Pharmaceutical and Biotechnology Sector is a Key Revenue Growth Driving Factor

Metabolomics are broadly utilized across different medical services and end-use industries. It has played a crucial part in the discovery and development of medicines. Rising demand for metabolomics in scientific organizations and research institutes for better analysis of diseases has helped the market to grow. For research & development of drugs and other biological processes, many government organizations and private firms are raising funds. It is also a major factor driving market revenue growth.

Restraint: High Cost of Equipment and Lack of Skilled Professionals Are Key Growth Restraining Factors

High cost of advanced tools & equipment and undeveloped healthcare facilities, especially in emerging countries are few factors expected to limit the metabolomics market revenue growth in the near future. Also, difficulty in managing complex data generated during scientific research, lack of skilled professionals, and very less healthcare expenditure in underdeveloped countries are likely to restrain market growth.

Product & Services Outlook:

Based on product & service, the global metabolomics market has been segmented into metabolomics separation tools, metabolomics detection tools, and bioinformatics tools & services. Metabolomics detection tools segment is expected to register steady revenue growth rate over the forecast period. Technological advancements in scientific instruments such as miniaturization, motorization, computerization, nutraceuticals, and metabolomics would propel this segment’s growth. Besides, ongoing development of healthcare infrastructure in emerging countries for providing better diagnosis and therapies to patients is also anticipated to bolster growth in the near future.

End-use Outlook:

Based on end-use, the global metabolomics market has been segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and others. Academic & research institutes segment accounted for largest revenue share in the global market in 2020. This growth is attributable to increasing number of research & development activities performed at academic & research institutes and rising funds provided by government bodies to these institutes. Metabolomics is considered to be an essential tool for research.

Pharmaceutical & biotechnology companies segment is expected to grow at a significant rate over the forecast period due to utilization of metabolomics in pharmaceutical companies for toxicology and disease pathology. It also helps in drug discovery processes and preclinical studies. Applications of metabolomics in the biotechnology sector such as nutrigenomics and functional genomics are also expected to contribute to market growth.

Related Reports:

Application Outlook:

Based on application, the global metabolomics market has been segmented into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicines, and others. Biomarker discovery segment contributed to the largest revenue share in 2020. Increasing use of metabolic biomarkers for determining pathophysiological medical conditions of a patient and increasing technological advancement are expected to drive revenue growth of the segment in the upcoming years. Additionally, metabolomics has become one of the most important tools for biomarker discovery, which in turn, is expected to support revenue growth of the segment.

Drug discovery segment, is expected to register significantly high revenue growth rate over the forecast period. Metabolomics is utilized by the pharmaceutical industry to research, discover, and develop new drugs. Use of metabolomics hypothesis for conducting toxicological studies on drugs is cost-effective, which is expected to drive revenue growth of the segment.

Indication Outlook

Based on indication, the global metabolomics market has been segmented into cancer, cardiovascular disorders, neurological disorders, metabolic disorders, inborn errors of metabolism, and other indications. Cancer segment is expected to account for the largest revenue share during the forecast period, owing to rising demand for cancer therapies and increasing number of patients suffering from cancer globally.

Regional Outlook:

Metabolomics market in North America accounted for the largest revenue share in 2020, attributed to presence of advanced research institutes and biotechnology laboratories in the region. High healthcare expenditure and rising adoption of advanced healthcare technology would also help the market to grow in this region. Presence of a large number of key players and surging research & development activities in the field of biomedical sciences are expected to propel revenue growth of the market in North America.

Metabolomics market in Asia Pacific is expected to register the fastest revenue CAGR over the forecast period. This growth is attributable to presence of various pharmaceutical companies in countries in the region. Additionally, growing geriatric population and rising prevalence of various chronic diseases are expected to drive revenue growth of the market in this region.

Competitive Landscape:

Competitive landscape of the global metabolomics market is moderately fragmented with a number of key players operating on global and regional levels. Key players are engaged in product development and strategic alliances to expand respective product portfolios and gain a robust footing in the global market. Some players in the market include Agilent Technologies, Bruker Corporation, Danaher Corporation (SCIEX), LECO Corporation, Shimadzu Corporation, Thermo Fisher Scientific, Waters Corporation, PerkinElmer Inc., Kore Technology Limited, and Human Metabolome Technologies Inc.

Some key developments in the market:

  • In September 2020, Bruker Corporation announced the acquisition of Canopy Biosciences, LLC, a leader in high multiplex biomarker imaging for immunology, immuno-oncology, and cell therapy. This acquisition would enhance Bruker’s offering in targeted multi-omics and fluorescence-based imaging techniques. The company’s global reach, complementary technologies, and application knowledge will help build on Canopy’s success to date.
  • In April 2020, Gilead Sciences, Inc. and Second Genome, a leader in microbiome science, announced that both companies entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis, and other diseases. These companies aim to identify potential new targets and drug candidates for the treatment of Inflammatory Bowel Disease (IBD).

Segments Covered in the Report:

This report offers historical data and forecasts revenue growth at a global, regional, & country level, and provides analysis of market trends in each of the sub-segments from 2018 to 2030. For this study, Reports and Data has segmented the global metabolomics market on the basis of product & services, end-use, application, indication, and region:

Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118241

Metabolomics Market Report Scope

Segments covered By Product & Service Outlook, End-Use Outlook, Application Outlook, Regional Outlook

By Product & Service Outlook

  • Polypropylene
  • Polyamide

By End-Use Outlook

  • Glass
  • Carbon
  • Others

By Application Outlook

  • Automotive
  • Consumer Goods
  • By Indication Outlook
  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Metabolic Disorders
  • Inborn Errors of Metabolism
  • Other Indications

Regional scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Buy quantitative research Report at discounted price - USD 1500 https://qyresearchmedical.com/report/checkout/118241/1500

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

About Us

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.

For Latest Update Follow Us:

URL - http://www.qyresearchmedical.com/

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Precedence Research